Interestingly, a dipeptidyl peptidase-4 (DPP-4) inhibitor could ameliorate aortic valve calcification by preventing IGF1 degradation, rendering it potentially a new agent for valve calcification disease (70, 71). The gene discussed is DPP4; the disease is aortic valve calcification.